Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

26
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

13
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

11
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
11
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

35
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
35
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

46
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis.

The Journal of rheumatology·2026
Same author

Comparison of [<sup>18</sup>F]fluorodeoxyglucose and [<sup>68</sup>Ga]Gallium DOTA-TATE in patients with active giant cell arteritis.

EJNMMI reports·2025
Same author

Incidentally detected noninfectious thoracic aortitis: A clinical approach.

Cleveland Clinic journal of medicine·2024
Same author

Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records.

The Lancet. Rheumatology·2024
Same author

Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis.

Atherosclerosis·2021
Same author

An update on the microbiome in vasculitis.

Current opinion in rheumatology·2020

Related Experiment Video

Updated: Aug 20, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K

Cardiovascular Disease in Large Vessel Vasculitis: Risks, Controversies, and Management Strategies.

Alison H Clifford1

  • 1Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.

Rheumatic Diseases Clinics of North America
|November 24, 2022
PubMed
Summary

Takayasu

Keywords:
Aortic aneurysmAtherosclerosisCardiovascular diseaseGiant cell arteritisLarge vessel vasculitisMyocardial infarctionStrokeTakayasu’s arteritis

More Related Videos

Author Spotlight: EasyFlow - An Economical and Adaptable Perfusion Bioreactor for Large Blood Vessel Culture
06:44

Author Spotlight: EasyFlow - An Economical and Adaptable Perfusion Bioreactor for Large Blood Vessel Culture

Published on: July 28, 2023

3.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

Related Experiment Videos

Last Updated: Aug 20, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Author Spotlight: EasyFlow - An Economical and Adaptable Perfusion Bioreactor for Large Blood Vessel Culture
06:44

Author Spotlight: EasyFlow - An Economical and Adaptable Perfusion Bioreactor for Large Blood Vessel Culture

Published on: July 28, 2023

3.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Immunology

Background:

  • Takayasu's arteritis (TAK) and giant cell arteritis (GCA) are primary large vessel vasculitides (LVV).
  • Both conditions share vascular targets, clinical features, and histopathology.
  • However, they affect distinct patient demographics: TAK affects young women, predominantly of Asian heritage, while GCA affects elderly individuals of northern European ancestry.

Purpose of the Study:

  • To compare and contrast cardiovascular diseases (CVD) in patients with TAK and GCA.
  • To explore the prevalence, risk factors, and mechanisms of CVD events in these patient groups.
  • To understand the roles of active vasculitis, vascular damage, and accelerated atherosclerosis in CVD development.

Main Methods:

  • This review synthesizes existing literature on CVD in TAK and GCA.
  • Comparative analysis of epidemiological data, clinical presentations, and pathophysiological mechanisms.
  • Discussion of current controversies and potential mitigation strategies for CVD in LVV.

Main Results:

  • Cardiovascular diseases are significantly elevated in patients with LVV.
  • Differences in CVD prevalence and risk factors exist between TAK and GCA patients, influenced by demographics and underlying disease processes.
  • Both active vasculitis and accelerated atherosclerosis contribute to CVD risk.

Conclusions:

  • Understanding the distinct CVD profiles in TAK and GCA is crucial for patient management.
  • Further research is needed to elucidate the interplay between vasculitis, vascular damage, and atherosclerosis.
  • Developing targeted mitigation strategies can help reduce the burden of CVD in patients with large vessel vasculitis.